Skip to main content

Table 2 Baseline characteristics of patients with ankylosing spondylitis and rheumatoid arthritis

From: High level of interleukin-32 gamma in the joint of ankylosing spondylitis is associated with osteoblast differentiation

  AS (n = 15) RA (n = 17) p-value
Age (years, mean ± SD) 32.9 ± 9.6 56.2 ± 10.4 <0.0001
Sex (male, n (%)) 12 (80.0 %) 2 (11.8 %) <0.0001
ESR (mm/h, mean ± SD) 53.7 ± 35.5 56.5 ± 31.3 NS
CRP (mg/dL, mean ± SD) 3.5 ± 3.5 2.9 ± 3.4 NS
Disease duration (years, mean ± SD) 5.2 ± 6.1 6.1 ± 6.3 NS
Eye involvement (n (%)) 5 (33.3 %) N/A  
HLA-B27 positive (n (%)) 13 (86.7 %) N/A  
BASDAI (mean ± SD) 4.3 ± 2.3 N/A  
mSASSS (mean ± SD) 15.8 ± 16.7 N/A  
Sacroiliitis grading (n (%))
 Grade 2 3 (20.0 %) N/A  
 Grade 3 9 (60.0 %) N/A
 Grade 4 3 (20.0 %) N/A
Current medications (n (%))
 MTX 7 (46.7 %) 14 (82.4 %) 0.062
 SSZ 8 (53.3 %) 1 (5.9 %) 0.005
 TNFi 3 (20 %) 1 (5.9 %) 0.319
 NSAID 13 (86.7 %) 16 (94.1 %) 0.589
  1. AS ankylosing spondylitis, BASDAI bath ankylosing spondylitis disease activity index, CRP C-reactive protein, ESR erythrocyte sedimentation rate, mSASSS modified Stoke Ankylosing Spondylitis Spine Score, MTX methotrexate, N/A not available, NS not significant, NSAID nonsteroidal anti-inflammatory drug, RA rheumatoid arthritis, SSZ sulfasalazine, TNFi tumor necrosis factor inhibitor